Delivery Order 75N93023D00001-75N93024F00006
- This is a $6,095,159.00 cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Advanced Bioscience Laboratories, Inc. (ABL) for expertise in professional pharmaceutical project management. The contract is issued under the larger Resources to Advance Pediatrics and HIV Prevention Science indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle. ABL, a manufacturer of biologics including vaccines and monoclonal antibodies,...
- This federal contract award, valued at $229,136.49, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services (HHS), to Advanced Bioscience Laboratories, Inc. (ABL). The contract is for ABL to assist NIAID in planning and implementing two separate meetings focused on potential ways to leverage private sector partnerships for pediatric formulation development. This contract is a delivery order under the larger "HIV...
- This federal contract award is to Advanced Bioscience Laboratories, Inc. (ABL) from the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services. The contract is for the performance of toxicity testing for HIV proteins as part of NIAID's Preclinical Development Support program. The contract is a cost-plus-fixed-fee delivery order with a ceiling value of $1,050,558.51 and a period of performance through April 7, 2017....
- This federal contract award to Advanced Bioscience Laboratories, Inc. (ABL) is for the cGMP manufacturing of a glycopeptide immunogen nanoparticle vaccine in support of preclinical development activities for the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH). The $4,683,305.11 cost-plus-fixed-fee contract has a period of performance through December 31, 2025. ABL, a for-profit manufacturer of goods, will provide a range of...
- This is a $3,500 firm-fixed-price delivery order awarded to Advanced Bioscience Laboratories, Inc. (ABL) by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health. The order is under the NIAID's Diagnostics Pre-Clinical Services Program Indefinite Delivery Vehicle (IDV), which has a total ceiling value of $24 million. ABL, a foreign-owned, for-profit manufacturer, is providing a range of preclinical development services to support...
- This is a federal contract award to Advanced Bioscience Laboratories, Inc. (ABL) from the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services (HHS). The contract, valued at $4,709,463.34, is for NIAID's Preclinical Development Support program focused on the immunoaffinity purification of HIV-1 envelope proteins. The contract is a Delivery Order with a Cost Plus Fixed Fee pricing type. This award does not have a...
- This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Advanced Bioscience Laboratories, Inc. (ABL), a for-profit manufacturer of goods. The $174,091.42 cost-plus-fixed-fee contract is for planning and implementation of a NIAID consultation on advancing the development of multipurpose prevention technologies (MPTs). This is a delivery order issued under NIAID's HIV Microbicides and Biomedical Prevention 2016-2021 IDIQ...
- This is a delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the U.S. Department of Health and Human Services (HHS), to Advanced Bioscience Laboratories, Inc. (ABL). The contract is for $1,812,395.46 and provides for the manufacture and characterization of vaccines and other biologics. The contract does not have a set-aside designation. ABL is a foreign-owned, for-profit organization that specializes in the development of gene...
- This federal contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Advanced Bioscience Laboratories, Inc. (ABL), a contract research and manufacturing organization. The $3,150,428.64 award is a delivery order under the HIV Microbicides and Biomedical Prevention 2016-2021 indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle. ABL will provide comprehensive resources for HIV...
- This is a federal contract award to Advanced Bioscience Laboratories, Inc. (ABL), a foreign-owned, for-profit manufacturer of goods, by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The contract, valued at $1,826,332.06, is for the provision of preclinical development support services related to the NIAID's infectious disease research and product development...
- 75N93023D00001Indefinite Delivery Contract
- 75N93023D00001-75N93024F00006Delivery Order
This is a federal contract award to Advanced Bioscience Laboratories, Inc. (ABL) by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), a civilian federal agency. The contract, valued at $4,328,663.00, is for expertise in the product development lifecycle, including services such as cGMP manufacturing of vaccines and biologics, process development, analytical testing, stability studies, and project management for infectious disease countermeasures. The contract is a Delivery Order under the Resources to Advance Pediatrics and HIV Prevention Science Indefinite Delivery Vehicle (IDV), a $98.9 million IDV with NIAID that covers a range of preclinical development support services. The contract does not have a set-aside designation, as ABL is a large, for-profit foreign-owned manufacturer of goods. ABL has supported various NIH programs, including HIV microbicides, pediatric drug formulation development, and cancer prevention initiatives, through its federal contract and grant awards.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $536.9k | 8/28/24 |